Early Briefing and Review: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc.

Thu Aug 29, 2013 8:25am EDT

* Reuters is not responsible for the content in this press release.

Early Briefing and Review: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc.

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

LONDON, August 29, 2013 /PRNewswire/ --

The U.S. equity market rebounded on Wednesday, August 28, 2013, after falling sharply in the previous trading session. The S&P 500 rose 0.27% on Wednesday to finish the day at 1,634.96. The healthcare sector ended on a mixed note as the broader market finished higher. The major movers in the sector included Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Zogenix Inc. (NASDAQ: ZGNX). AAAResearchReports.com has released free charting and technical research on these aforementioned companies. Register to read these reports at:


Shares in Pfizer Inc. moved higher on Wednesday, reversing some of their recent losses. The company's shares ended the session 0.77% higher at $28.21 after oscillating between $27.81 and $28.49. A total of 29.22 million shares were traded which is less than the daily average volume of 55.83 million. The company's shares have dipped 0.46% in the last three trading sessions, outperforming the S&P 500 which has lost 1.72% during the same period. Moreover, the company's shares are trading above their 200-day moving average. Sign up for free report on PFE at:


Merck & Company Inc.'s shares fluctuated between gains and losses on Wednesday before closing the day nearly flat at $47.09. The company's shares traded between $46.47 and $47.40 before ending the day 0.04% lower than the previous  closing price of $47.11. A total of 9.81 million shares traded, which is below the daily average volume of 15.13 million. The company's shares have declined by 1.11% during the last three months, compared to a loss of 1.51% in the S&P 500 during the same period. Despite the recent losses, Merck & Company Inc.'s stock continues to trade above its 200-day moving average. MRK free technical report can be accessed by signing up at:


AbbVie Inc.'s stock ended slightly lower on Wednesday, finishing at $42.56, down 0.16% from its previous closing price of $42.63. The company's shares oscillated between $42.35 and $42.81. A total of 3.00 million shares were traded, which is below the daily average volume of 4.47 million. AbbVie Inc.'s shares have lost 4.98% in the last one month, underperforming the S&P 500 which has lost 3.35% during the same period. Further, the company's shares are trading below its 50-day moving average. A free report on ABBV can be accessed by registering at:


On Wednesday, shares in Zogenix Inc. rose sharply, tracking gains in the broader market. The company's shares ended the day at $1.56, up 1.96%, after fluctuating between $1.53 and $1.58. A total of 0.10 million shares were traded, which is below the daily average volume of 0.45 million. Moreover, the company's shares have gained 2.63% in the previous three months, outperforming the S&P 500, which has fallen by 1.51% during the same period. Moreover, Zogenix Inc.'s shares are trading below their 50-day and 200-day moving averages. Register with AAA Research Reports and download research on ZGNX for free at:




  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


SOURCE AAA Research Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.